65,437 trials
Pompe Disease (Late-onset) · Glycogen Storage Disease Type II (GSD-II) · Acid Maltase Deficiency Disease
Primary: Summary of Patients Reporting Treatment-Emergent Adverse Events — 60; 30; 32; 17 participants
Pain · Osteoarthritis · Low Back Pain
Primary: Number of Subjects With Treatment-emergent Adverse Events (TEAE) — 907 participants
Rhinitis, Allergic, Perennial
Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score Averaged Over the 6-week Treatment Period in Patients With Perennial Allergic Rhinitis — -0.37; -0.44 Score on…
Acne
Primary: Median Change in Total Propionibacterium Acne (P.Acne) Counts — -1.26; -0.08; -1.58; -0.67 P. acne counts
Tennis Elbow · Epicondylitis, Lateral Humeral
Primary: Pain (at 1 Week): Visual Analogue Scale(0 to 10) — 7.166; 4.5 Units on a scale — p=<0.0001
Healthy
Primary: Percent Change in Diameter of Radial Artery as a Dose Test for Nitroglycerin — -0.8; -0.2; 6.4; 2.5 percent diameter change
Atopic Dermatitis
Primary: Change From Baseline in the m-EASI (Eczema Area Severity Index) Score. — 5.04; 4.77 units of a 0-12 scale — p=<0.05
AIDS · HIV Infections
Primary: Change in Visceral Adipose Tissue Area From Baseline to 18 Months — -22; -4 centimeters squared — p=0.049
Tetanus · Diphtheria · Pertussis
Primary: Percentage of Participants With at Least 1 Solicited Injection Site and Systemic Reactions Post-Vaccination — 89; 88; 2; 29 Percentage of Participants
Breast Cancer
Primary: Number of Patients With Pathological Complete Response (Pathological Complete Response Rate) — 13 participants
Diabetes Mellitus, Type 2
Primary: Change From Baseline in A1C at Week 18 — -0.48; -0.36; 0.12 percent — p=<0.001
Nasal Polyps
Primary: Change From Baseline 24-hour Urinary Free Cortisol Level — 49.5; 39.6; 49.8; 1.5 mcg/hour — p=0.258
Stroke · Dysphagia
Primary: Change in Duration of Superior Hyolaryngeal Movement — .213; .233 seconds
Puberty, Precocious
Primary: Percentage of Subjects (n/N) With Suppression of Clinical Sexual Characteristics According to Tanner Staging (Breast Development in Females) — 81.8; 80.9; 87.8; 82.8…
Alzheimer Disease
Primary: Number of Successful Memory Tasks Completed Over Study Period. — 5; 0 memory tasks